AU750207B2 - Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof - Google Patents
Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof Download PDFInfo
- Publication number
- AU750207B2 AU750207B2 AU80591/98A AU8059198A AU750207B2 AU 750207 B2 AU750207 B2 AU 750207B2 AU 80591/98 A AU80591/98 A AU 80591/98A AU 8059198 A AU8059198 A AU 8059198A AU 750207 B2 AU750207 B2 AU 750207B2
- Authority
- AU
- Australia
- Prior art keywords
- prodrug
- pharmaceutical composition
- cyclodextrin
- fosphenytoin
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000651 prodrug Substances 0.000 title claims abstract description 77
- 229940002612 prodrug Drugs 0.000 title claims abstract description 77
- 229940079593 drug Drugs 0.000 title claims description 80
- 239000003814 drug Substances 0.000 title claims description 80
- 239000000203 mixture Substances 0.000 title claims description 37
- 238000004519 manufacturing process Methods 0.000 title description 31
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 105
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229940097362 cyclodextrins Drugs 0.000 claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 36
- 239000013543 active substance Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 12
- 229960000693 fosphenytoin Drugs 0.000 claims description 85
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 claims description 80
- 239000008380 degradant Substances 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 12
- -1 steroid phosphates Chemical class 0.000 claims description 10
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 3
- 229960005091 chloramphenicol Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 125000004964 sulfoalkyl group Chemical group 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 84
- 229960002036 phenytoin Drugs 0.000 description 84
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 58
- 230000015556 catabolic process Effects 0.000 description 23
- 238000006731 degradation reaction Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 5
- 238000005057 refrigeration Methods 0.000 description 5
- 239000003708 ampul Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010591 solubility diagram Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 150000004683 dihydrates Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- FEJIIZAOQRTGPC-UHFFFAOYSA-N 5,5-diphenylimidazolidin-4-one Chemical compound O=C1NCNC1(C=1C=CC=CC=1)C1=CC=CC=C1 FEJIIZAOQRTGPC-UHFFFAOYSA-N 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- KZVRXPPUJQRGFN-UHFFFAOYSA-N N-carbamoylglycine Chemical class NC(=O)NCC(O)=O KZVRXPPUJQRGFN-UHFFFAOYSA-N 0.000 description 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000178960 Paenibacillus macerans Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 101150080176 SBE1 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5090997P | 1997-06-13 | 1997-06-13 | |
| US60/050909 | 1997-06-13 | ||
| PCT/US1998/011596 WO1998056422A1 (en) | 1997-06-13 | 1998-06-12 | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8059198A AU8059198A (en) | 1998-12-30 |
| AU750207B2 true AU750207B2 (en) | 2002-07-11 |
Family
ID=21968241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU80591/98A Expired AU750207B2 (en) | 1997-06-13 | 1998-06-12 | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6133248A (https=) |
| EP (1) | EP0986403B1 (https=) |
| JP (1) | JP4439596B2 (https=) |
| AT (1) | ATE253941T1 (https=) |
| AU (1) | AU750207B2 (https=) |
| DE (1) | DE69819721T2 (https=) |
| ES (1) | ES2210769T3 (https=) |
| PT (1) | PT986403E (https=) |
| WO (1) | WO1998056422A1 (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE485837T1 (de) * | 2000-08-03 | 2010-11-15 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| PE20020300A1 (es) * | 2000-08-22 | 2002-05-10 | Pharmacia Corp | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco |
| PE20020578A1 (es) | 2000-10-10 | 2002-08-14 | Upjohn Co | Una composicion de antibiotico topico para el tratamiento de infecciones oculares |
| US6566556B2 (en) * | 2000-12-19 | 2003-05-20 | Nippon Shokubai Co., Ltd. | Method for production of alkanolamine and apparatus therefor |
| MXPA03011793A (es) * | 2001-06-29 | 2004-04-02 | Maxygen Holdings Ltd | Formulaciones de interferon. |
| US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| PT1456377T (pt) * | 2001-12-20 | 2019-09-10 | Merck Sharp & Dohme | Composições de syn3 e processos |
| MXPA04008171A (es) * | 2002-02-22 | 2004-11-26 | Pharmacia Corp | Formulacion oftalmica con sistema de goma. |
| BR0307898A (pt) * | 2002-02-22 | 2004-12-07 | Pharmacia Corp | Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio |
| ATE534373T1 (de) | 2003-10-10 | 2011-12-15 | Antares Pharma Ipl Ag | Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut |
| US8129346B2 (en) | 2004-04-15 | 2012-03-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
| EP2030981B1 (en) * | 2004-05-10 | 2014-07-09 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
| PT2260835E (pt) * | 2004-12-07 | 2013-05-28 | Onyx Therapeutics Inc | Composição para inibição do proteassoma |
| US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| MY171061A (en) * | 2005-11-09 | 2019-09-24 | Onyx Therapeutics Inc | Compounds for enzyme inhibition |
| US20070111965A1 (en) * | 2005-11-15 | 2007-05-17 | Kipp James E | Compositions comprising lipoxygenase inhibitors and cyclodextrin |
| US20070135586A1 (en) * | 2005-12-09 | 2007-06-14 | Shreyas Chakravarti | Polyamide blend compositions formed article and process thereof |
| CN101426475A (zh) | 2006-04-21 | 2009-05-06 | 安塔雷斯制药Ipl股份公司 | 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法 |
| CA2657213C (en) | 2006-06-19 | 2017-01-03 | Proteolix, Inc. | Peptide epoxyketones for proteasome inhibition |
| US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| EP2061458B1 (en) * | 2006-09-15 | 2014-12-10 | Regents of the University of Minnesota | Topiramate compositions and methods for their use |
| JP5681485B2 (ja) | 2007-04-27 | 2015-03-11 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法 |
| US20090082400A1 (en) * | 2007-07-31 | 2009-03-26 | Ving Lee | Soluble pyrone analogs methods and compositions |
| KR20170125413A (ko) | 2007-10-04 | 2017-11-14 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| CA2762321A1 (en) * | 2008-05-19 | 2009-11-26 | Texcontor Etablissement | Fosphenytoin composition |
| EP3090737A1 (en) | 2008-10-21 | 2016-11-09 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| US10463677B2 (en) | 2008-11-07 | 2019-11-05 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| CA2761455C (en) | 2009-05-13 | 2018-06-12 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
| PL2434886T3 (pl) | 2009-05-29 | 2020-05-18 | Cydex Pharmaceuticals, Inc. | Kompozycje do wstrzykiwania melfalanu zawierające pochodną cyklodekstryny i sposoby ich wytwarzania i stosowania |
| US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
| US8431576B2 (en) | 2009-06-25 | 2013-04-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| CA2937222C (en) * | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
| EP2542238B1 (en) | 2010-03-01 | 2015-08-12 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| NZ602872A (en) | 2010-04-07 | 2014-05-30 | Onyx Therapeutics Inc | Crystalline peptide epoxyketone immunoproteasome inhibitor |
| ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
| DE102011011028A1 (de) * | 2011-02-11 | 2012-08-16 | Ditter Plastic Gmbh + Co. Kg | Frontplatte mit darin eingespritztem Lichtleiter |
| HUE065359T2 (hu) | 2011-03-18 | 2024-05-28 | Alkermes Pharma Ireland Ltd | Szorbitán-észtereket tartalmazó gyógyászati készítmények |
| DK2758052T3 (en) | 2011-09-18 | 2018-05-28 | Euro Celtique Sa | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide |
| JP5952912B2 (ja) | 2011-12-15 | 2016-07-13 | アルカーメス ファーマ アイルランド リミテッド | 二級アミン化合物のプロドラッグ |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| WO2013123254A1 (en) | 2012-02-15 | 2013-08-22 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| RU2615385C2 (ru) | 2012-02-28 | 2017-04-04 | Сидекс Фармасьютикалс, Инк. | Композиции алкилированного циклодекстрина и способы их получения и применения |
| ES2950418T3 (es) | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden alcohol bencílico |
| JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
| ES2765036T3 (es) | 2012-03-19 | 2020-06-05 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden esteres de ácidos grasos |
| US20140105921A1 (en) | 2012-07-09 | 2014-04-17 | Onyx Therapeutics, Inc. | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors |
| EP2897592B1 (en) | 2012-09-19 | 2020-02-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| KR102112119B1 (ko) | 2012-10-22 | 2020-05-19 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| BR112016021535A8 (pt) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| PT3183295T (pt) | 2014-08-22 | 2023-11-03 | Cydex Pharmaceuticals Inc | Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas |
| GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| KR20210105380A (ko) | 2018-12-18 | 2021-08-26 | 먼디파머 인터내셔널 코포레이션 리미티드 | 다발성 골수종을 치료하기 위한 화합물 |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| CN110279664B (zh) * | 2019-07-30 | 2021-09-03 | 四川农业大学 | 一种氟苯尼考包合物冻干粉针剂及其制备方法 |
| US20230000997A1 (en) | 2019-08-06 | 2023-01-05 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
| JP2023551145A (ja) | 2020-11-18 | 2023-12-07 | ベクソン バイオメディカル，インク． | 医薬化合物の錯化剤塩製剤 |
| AU2020480182B2 (en) | 2020-12-04 | 2025-02-27 | Sichuan Credit Pharmaceutical Co., Ltd | Fosphenytoin sodium solid composition, lyophilization method, and use of fosphenytoin sodium solid composition |
| CN118161457A (zh) * | 2020-12-04 | 2024-06-11 | 四川科瑞德制药股份有限公司 | 磷苯妥英钠固体组合物、冻干方法、及其用途 |
| WO2023225113A1 (en) * | 2022-05-18 | 2023-11-23 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios |
| EP4705341A1 (en) | 2023-05-05 | 2026-03-11 | Euro-Celtique S.A. | Combinations for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU191101B (en) * | 1983-02-14 | 1987-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups |
| US4616008A (en) * | 1984-05-02 | 1986-10-07 | Takeda Chemical Industries, Ltd. | Antibacterial solid composition for oral administration |
| JPS61165322A (ja) * | 1985-01-14 | 1986-07-26 | Microbial Chem Res Found | スパガリン類の注射用凍結乾燥製剤 |
| US4728509A (en) * | 1985-08-19 | 1988-03-01 | Takeda Chemical Industries, Ltd. | Aqueous liquid preparation |
| US4925860A (en) * | 1987-08-05 | 1990-05-15 | E. I. Du Pont De Nemours And Company | Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester |
| DE3938227C1 (en) * | 1989-11-17 | 1991-05-02 | Dolorgiet Gmbh & Co Kg, 5205 St Augustin, De | Oral antiinflammatory and analgetic pharmaceutical compsn. - comprises magnesium ibuprofen dissolved in mixt. of water, propane-1,2-diol and glycerol |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| DE839528T1 (de) * | 1996-10-29 | 1998-10-22 | Staroil Ltd | Mundlösliche Zusammensetzungen die N-Acetylcystein und Cyclodextrin enthalten |
-
1998
- 1998-06-12 US US09/096,747 patent/US6133248A/en not_active Expired - Lifetime
- 1998-06-12 AT AT98928901T patent/ATE253941T1/de active
- 1998-06-12 ES ES98928901T patent/ES2210769T3/es not_active Expired - Lifetime
- 1998-06-12 EP EP98928901A patent/EP0986403B1/en not_active Expired - Lifetime
- 1998-06-12 PT PT98928901T patent/PT986403E/pt unknown
- 1998-06-12 JP JP50289599A patent/JP4439596B2/ja not_active Expired - Lifetime
- 1998-06-12 AU AU80591/98A patent/AU750207B2/en not_active Expired
- 1998-06-12 DE DE69819721T patent/DE69819721T2/de not_active Expired - Lifetime
- 1998-06-12 WO PCT/US1998/011596 patent/WO1998056422A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69819721D1 (de) | 2003-12-18 |
| PT986403E (pt) | 2004-04-30 |
| JP4439596B2 (ja) | 2010-03-24 |
| JP2002511861A (ja) | 2002-04-16 |
| ES2210769T3 (es) | 2004-07-01 |
| DE69819721T2 (de) | 2004-09-23 |
| WO1998056422A1 (en) | 1998-12-17 |
| EP0986403B1 (en) | 2003-11-12 |
| ATE253941T1 (de) | 2003-11-15 |
| EP0986403A1 (en) | 2000-03-22 |
| US6133248A (en) | 2000-10-17 |
| AU8059198A (en) | 1998-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU750207B2 (en) | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof | |
| CA2119154C (en) | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof | |
| KR100372988B1 (ko) | 보리코나졸 함유 제약 제제 | |
| US5134127A (en) | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof | |
| Mosher et al. | Complexation and cyclodextrins | |
| WO1994002518A9 (en) | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof | |
| KR20030068203A (ko) | 사이클로덱스트린 제제 | |
| EP0811386B1 (en) | Method of selecting a salt for making an inclusion complex | |
| KR101037313B1 (ko) | 메스나를 함유하는 안정한 액체 옥스아자포스포린 조성물 | |
| Narisawa et al. | Increased shelf‐life of fosphenytoin: Solubilization of a degradant, phenytoin, through complexation with (SBE) 7m‐β‐CD | |
| CA2519418A1 (en) | New injectable formulations containing progesterone | |
| JP3597239B2 (ja) | 安定な点眼剤 | |
| EP2994109B1 (en) | Aqueous ophthalmic formulations based on azithromycin | |
| Stella | Sbe7-β-CD, a New, Novel and Safe Polyanionic β-Cyclodextrin Derivative: Characterization And Biomedical Applications. | |
| Stella | SBE7-B-CD, A NEW, NOVEL AND SAFE POLYANIONIC B | |
| MXPA99012075A (en) | Pharmaceutical formulations containing voriconazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CYDEX INC. Free format text: THE FORMER OWNER WAS: THE UNIVERSITY OF KANSAS |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |